Policy Making: How the Advisory Committee on Immunization Practices Reached Recent Decisions

Abstract

With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunoprophylaxis, and immunotherapy. This column is intended to help you ensure proper immunologic drug use in your practice.

Keywords

Advisory Committee on Immunization Practices immunization policy making vaccines

Get full access to this article

View all access options for this article.

References

Grabenstein

J.D.

American immunization policies: Actions speak louder than words. Hosp Pharm. 1993; 28: 1233–4, 1237–40.

United States Code, Title 42, Section 217.

Grabenstein

J.D.

Immunologic necessities: Diluents, adjuvants, and excipients. Hosp Pharm. 1996; 31: 1387–8, 1390,1392, 1397–8,1401.

Grabenstein

J.D.

Clinical management of hypersensitivities to vaccine components. Hosp Pharm. 1997; 32: 77–8, 81–4,87.

Grabenstein

J.D.

ImmunoFacts: Vaccines and Immunologic Drugs. St. Louis: Facts and Comparisons, Inc.; February 2000.

Centers for Disease Control and Prevention. Thimerosal in vaccines: A joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR. 1999; 48: 563–5.

Centers for Disease Control and Prevention. Recommended childhood immunization schedule—United States, 1999. MMWR. 1999; 48: 8–16.

Grabenstein

J.D.

How to interpret immunization schedules and records. Hosp Pharm. 1999; 34: 482–6, 489–91.

Advisory Committee on Immunization Practices. Revised recommendations for routine poliomyelitis prevention. MMWR. 1999; 48: 590.

10.

Advisory Committee on Immunization Practices. Prevention of hepatitis A through active or passive immunization. MMWR. 1999; 48(RR-12): 1–37.

11.

Advisory Committee on Immunization Practices. Control and prevention of meningococcal disease. MMWR. 1997; 46(RR-5): 1–21.

12.

Harrison

L.H.

, Dwyer

D.M.

, Maples

C.T.

, Billmann

Risk of meningococcal infection in college students. JAMA. 1999; 281: 1906–10.

13.

Task Force on Community Preventive Services. Vaccine-preventable diseases: Improving vaccination coverage in children, adolescents, and adults. MMWR. 1999; 48(RR-8): 1–15.

14.

Advisory Committee on Immunization Practices. Prevention and control of influenza. MMWR. 1999; 48(RR-4): 1–28.

15.

Christopher

G.W.

, Cieslak

T.J.

, Pavlin

J.A.

Biological warfare: A historical perspective. JAMA. 1997; 278: 412–17.

16.

Inglesby

T.V.

, Henderson

D.A.

, Bartlett

J.G.

and the Working Group on Civilian Biodefense. Anthrax as a biological weapon: Medical and public health management. JAMA. 1999; 281: 1735–45.

17.

Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management—United States, 1998. MMWR. 1999; 48: 69–74.

18.

Henderson

D.A.

, Inglesby

T.V.

, Bartlett

J.G.

and the Working Group on Civilian Biodefense. Smallpox as a biological weapon: Medical and public health management. JAMA. 1999; 281: 2127–37.

19.

Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. MMWR. 1999; 48(RR-2): 1–23.

20.

Grabenstein

J.D.

Rotavirus: Leading cause of pediatric gastroenteritis. Hosp Pharm. 1997; 32: 1480, 1484–6,1489.

21.

Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine—United States, 1998–1999. MMWR 1999; 48: 577–81.

22.

Grabenstein

J.D.

Immunologic resources: An annotated bibliography. Hosp Pharm. 1998; 33: 323–4, 327–30,332–3.